Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Boehringer Ingelheim
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
July 29, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer Ingelheim produces its own green energy
July 08, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 28, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
May 06, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Less than half of veterinary professionals feel their profession is appreciated
April 25, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
SPEVIGO® approved for expanded indications in China and the US
March 19, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
February 19, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer expands production site in Greece for new medicine
January 11, 2024
From
Boehringer Ingelheim
Via
GlobeNewswire
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
November 24, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
November 22, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
October 02, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
September 14, 2023
From
Boehringer Ingelheim
Via
Business Wire
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
August 01, 2023
From
Boehringer Ingelheim
Via
Business Wire
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
July 25, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
May 10, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
May 09, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 29, 2023
From
Boehringer Ingelheim
Via
Business Wire
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
January 17, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
January 09, 2023
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim announces appointments to Board of Managing Directors
December 20, 2022
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
December 19, 2022
From
Boehringer Ingelheim
Via
Business Wire
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
December 13, 2022
From
Boehringer Ingelheim
Via
Business Wire
University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs
October 20, 2022
From
Boehringer Ingelheim
Via
Business Wire
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
October 05, 2022
From
Boehringer Ingelheim
Via
Business Wire
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
August 03, 2022
From
Boehringer Ingelheim
Via
Business Wire
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
July 06, 2022
From
Boehringer Ingelheim
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.